UroGen Pharma URGN Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about UroGen Pharma's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is UroGen Pharma's other accrued liabilities?
- UroGen Pharma (URGN) reported other accrued liabilities of $5.45M in Q1 2026.
- How has UroGen Pharma's other accrued liabilities changed year-over-year?
- UroGen Pharma's other accrued liabilities increased by 15.7% year-over-year, from $4.71M to $5.45M.
- What is the long-term trend for UroGen Pharma's other accrued liabilities?
- Over 5 years (2020 to 2025), UroGen Pharma's other accrued liabilities has grown at a 22.8% compound annual growth rate (CAGR), from $1.86M to $5.19M.
- What does other accrued liabilities mean?
- This captures miscellaneous short-term obligations that do not fit into standard categories like accounts payable or accrued compensation. It often includes items such as customer deposits, short-term tax provisions, or other minor contractual liabilities. It provides insight into the breadth of the company's short-term financial commitments.